Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiyen Biotech Co's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$1,503 Mil.
Taiyen Biotech Co's quarterly Other Stockholders Equity
increased
from Jun. 2025 (NT$1,501 Mil) to Sep. 2025 (NT$1,502 Mil) and
increased
from Sep. 2025 (NT$1,502 Mil) to Dec. 2025 (NT$1,503 Mil).
Taiyen Biotech Co's annual Other Stockholders Equity
increased
from Dec. 2023 (NT$1,434 Mil) to Dec. 2024 (NT$1,462 Mil) and
increased
from Dec. 2024 (NT$1,462 Mil) to Dec. 2025 (NT$1,503 Mil).
Taiyen Biotech Co Other Stockholders Equity Related Terms
Taiyen Biotech Co Other Stockholders Equity Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Other Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Stockholders Equity of NT$1,503 Mil mean?
Taiyen Biotech Co (TPE:1737) has a Other Stockholders Equity of NT$1,503 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Taiyen Biotech Co and its competitors.
Is Taiyen Biotech Co's Other Stockholders Equity too high?
Taiyen Biotech Co's current Other Stockholders Equity is NT$1,503 Mil. Overall, Taiyen Biotech Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Other Stockholders Equity compare to PG and CL?
Taiyen Biotech Co's Other Stockholders Equity of NT$1,503 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Consumer Packaged Goods company?
A good Other Stockholders Equity depends on the Consumer Packaged Goods industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Taiyen Biotech Co and its competitors. Taiyen Biotech Co's current Other Stockholders Equity is NT$1,503 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$32.06, compared to a current price of NT$32.00 — trading 0.2% below its estimated fair value. The current Other Stockholders Equity is NT$1,503 Mil. Taiyen Biotech Co's overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Other Stockholders Equity is NT$1,503 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be undervalued.
The current stock price of NT$32.00 is trading 0.2% below its estimated GF Value™ of NT$32.06.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Other Stockholders Equity: NT$1,503 Mil
GF Value™: NT$32.06 vs. price of NT$32.00 (0.2% below fair value)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
82GF Score
Get the complete analysis for TPE:1737
Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
